EUVIMEDOpdag EUVIMED
Open access · CC BY-NC 4.0

A 6‐year experience of Zephyr endobronchial valves for severe emphysema in an Australian single‐centre cohort

Michael V Brown iD, Arash Badiei, Hubertus Jersmann, Andrew Fon, Chong G Chew, Brett Lorraine, Phan Nguyen

Internal Medicine Journal · 2024

DOI: 10.1111/imj.16319 ↗

At a glance

Journal article in Internal Medicine Journal, 2024. Written by Michael V Brown and 6 co-authors. Institution: Department of Thoracic Medicine, Royal Adelaide Hospital, Adelaide, South Australia, Australia. Major MEDLINE topics: Pulmonary Emphysema, Pneumonectomy. Cited 3 times so far (Crossref); 33 references. The full text is freely available (open access, CC BY-NC 4.0).

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background

Endobronchial valve (EBV) insertion for lung volume reduction is a management option for patients with severe emphysema. One‐way valves cause lobar deflation and improve lung function, exercise capacity and quality of life.

Aims

To retrospectively analyse and compare the outcomes of the first 57 patients treated with EBVs between 2015 and 2021 at the Royal Adelaide Hospital to international standards.

Methods

Clinical outcomes of forced expiratory volume in 1 s (FEV1), residual volume (RV), treated lobe volume reduction (TLVR) and 6‐min walk distance (6MWD) at 3, 6 and 12 months after valve insertion were reviewed against established minimally clinically important differences (MCIDs). Complications and subjective breathlessness measured by Borg scores were also reviewed.

Results

Fifty‐seven patients were included. At 12 months, 77.2% achieved TLVR. FEV1 improved by 170 mL (95% confidence interval (CI): 100–250, P < 0.001), 80 mL (95% CI: 10–150, P = 0.019) and 40 mL (95% CI: −60 to 130, P 0.66) at 3, 6 and 12 months respectively. RV improved by −610 mL (95% CI: −330 to −900, P < 0.0001) at 3 months, −640 mL (95% CI: −360 to −920, P < 0.0001) at 6 months and −360 mL (95% CI: −60 to −680, P = 0.017) at 12 months. 6MWD improved by 57.34 m (95% CI: 36.23–78.45, P < 0.0001) and 44.93 m (95% CI: 7.19–82.67, P = 0.02) at 3 and 6 months. Borg score improved by −0.53 (95% CI: 0.11 to −1.2, P = 0.11) and −0.49 (95% CI: 0.17 to −1.15, P = 0.16) at 3 and 6 months. Complication rates aligned with international standards with mucous/infection (26.3%) and pneumothorax (17.5%) as the most common. Subgroup analysis signalled improved outcomes in patients with heterogeneous emphysema.

Conclusion

Our study represents the first publicly funded Australian analysis of EBVs. The results align with international prospective trials demonstrating improved lung function and exercise capacity. Australians with severe emphysema and gas trapping should be referred to a multidisciplinary centre for consideration of EBVs.

Subjects

MeSH terms (MEDLINE)

Pulmonary EmphysemaPneumonectomyHumansMaleFemaleRetrospective StudiesMiddle AgedAgedAustraliaForced Expiratory VolumeTreatment OutcomeQuality of LifeExercise ToleranceWalk TestBronchoscopySeverity of Illness IndexProstheses and Implants

Author keywords

bronchoscopyemphysemaendobronchial valvelung volume reductionsmoking

Authors and institutions

  • Department of Thoracic Medicine, Royal Adelaide Hospital, Adelaide, South Australia, Australia.
  • Faculty of Health and Medical Sciences, Adelaide Medical School, University of Adelaide, Adelaide, South Australia, Australia.
  • Department of Respiratory and Sleep Medicine, Queen Elizabeth Hospital, Adelaide, South Australia, Australia.
  • Department of Nuclear Medicine, Royal Adelaide Hospital, Adelaide, South Australia, Australia.
  • SA Medical Imaging, Royal Adelaide Hospital, Adelaide, South Australia, Australia.

ORCID profiles: Michael V Brown

Cite

APA

Brown, M. V., Badiei, A., Jersmann, H., Fon, A., Chew, C. G., Lorraine, B., & Nguyen, P. (2024). A 6‐year experience of Zephyr endobronchial valves for severe emphysema in an Australian single‐centre cohort. Internal Medicine Journal. https://doi.org/10.1111/imj.16319

Vancouver

Brown MV, Badiei A, Jersmann H, Fon A, Chew CG, Lorraine B, et al. A 6‐year experience of Zephyr endobronchial valves for severe emphysema in an Australian single‐centre cohort. Internal Medicine Journal. 2024. doi:10.1111/imj.16319

BibTeX
@article{Brown2024,
  author = {Brown, Michael V and Badiei, Arash and Jersmann, Hubertus and Fon, Andrew and Chew, Chong G and Lorraine, Brett and Nguyen, Phan},
  title = {A 6‐year experience of Zephyr endobronchial valves for severe emphysema in an Australian single‐centre cohort},
  journal = {Internal Medicine Journal},
  year = {2024},
  doi = {10.1111/imj.16319}
}
Start for free →